FDA Will Propose Drug GMP Quality Management Systems By December
This article was originally published in The Tan Sheet
Executive Summary
FDA expects to release a draft on improving the agency's drug GMP management systems by Dec. 1
You may also be interested in...
PAT Data Will Not Be Evaluated During Drug Inspections – FDA
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference
PAT Data Will Not Be Evaluated During Drug Inspections – FDA
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference
PAT Data Will Not Be Evaluated During Drug Inspections – FDA
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference